Abstract: Bispecific antibody refers to an antibody that can bind to different types of antigens or two different epitopes on the same antigen. Therefore, compared to monospecific antibodies, bispecific antibodies are characterized by enhanced anti-tumor effects, low adverse effects and low antibody dosage. Lung cancer is one of the main study populations for bispecific antibodies, and the advent and approval of amivantamab to market provides a new option for the treatment of lung cancer patients. This paper reviewed the characteristics of bispecific antibodies in tumor therapy and the research progress of bispecific antibodies in lung cancer, so as to provide some new ideas for the clinical treatment of lung cancer.